 |
市場調查報告書
商品編碼
1495558
西羅莫司市場 - 按應用（器官移植排斥、淋巴管平滑肌瘤病）、給藥途徑（注射、片劑）、劑量（0.5毫克、1毫克、2毫克）、配銷通路（醫院藥房、零售藥局） - 全球預測（2024年- 2032年）Sirolimus Market - By Application (Organ Transplant Rejection, Lymphangioleiomyomatosis), Route of Administration (Injection, Tablets), Dosage (0.5mg, 1mg, 2mg), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) - Global Forecast (2024 - 2032) |
||||||
西羅莫司市場規模預計在2024 年至2032 年間將以3.6% 的複合年成長率擴大。的成長。癌症、淋巴管平滑肌瘤病 (LAM) 和冠狀動脈疾病等各種疾病的盛行率不斷上升，刺激了對西羅莫司療法的需求。
根據聯合器官共享網路的資料，2023年美國進行了超過46,000例器官移植。正在進行的研究西羅莫司治療各種疾病功效的臨床試驗正在增加其市場吸引力。藥物傳輸技術的重大進步和學名藥的引入正在提高可及性和可負擔性，進一步推動西羅莫司藥物的廣泛採用。
西羅莫司產業分為應用、給藥途徑、劑量、配銷通路和地區。
根據應用，淋巴管平滑肌瘤病(LAM) 領域的市場規模預計在2024 年至2032 年間將以3.4% 的複合年成長率成長。女性的罕見進行性肺部疾病。西羅莫司已被證明可以穩定 LAM 患者的肺功能並減輕症狀。人們越來越認知到西羅莫司作為 LAM 的治療選擇，以及正在進行的臨床研究將進一步推動該細分市場的成長。
就給藥途徑而言，由於對標靶和控制藥物傳遞的需求不斷成長，特別是在需要免疫抑制的移植患者中，注射領域的西羅莫司行業到2032年的複合年成長率將達到3.8 %。西羅莫司的注射製劑可提供精確的劑量和快速起效，使其適合移植後護理。這些注射也確保藥物的全身分佈，最佳化治療結果。注射技術的顯著進步提高了患者的便利性和依從性，將促進該細分市場的成長。
從區域來看，由於需要免疫抑制治療的慢性疾病（包括器官移植和自體免疫疾病）盛行率不斷上升，預計歐洲西羅莫司市場從 2024 年到 2032 年將增加 3.2%。此外，該地區在腫瘤學領域也擴大採用西羅莫司來治療各種癌症。此外，政府支持器官捐贈和移植的有利舉措，加上醫療基礎設施的進步，將進一步刺激該地區對西羅莫司藥物的需求。
目錄
第 1 章：方法與範圍
第 2 章：執行摘要
第 3 章：產業洞察
- 產業生態系統分析
- 產業影響力
- 成長動力
- 器官移植發生率上升
- 針對不同適應症的有前途的管道
- 藥物輸送系統的進步
- 產業陷阱與挑戰
- 與西羅莫司相關的不良反應
- 成長動力
- 成長潛力分析
- 監管環境
- 技術景觀
- 波特的分析
- PESTEL分析
第 4 章：競爭格局
- 介紹
- 公司市佔率分析
- 競爭定位矩陣
- 戰略展望矩陣
第 5 章：市場估計與預測：按應用分類，2021 - 2032
- 主要趨勢
- 器官移植排斥反應
- 淋巴管平滑肌瘤病 (LAM)
- 西羅莫司塗層球囊和導管裝置
第 6 章：市場估計與預測：按管理途徑，2021 年至 2032 年
- 主要趨勢
- 注射
- 平板電腦
第 7 章：市場估計與預測：按劑量，2021-2032
- 主要趨勢
- 0.5毫克
- 1毫克
- 2毫克
第 8 章：市場估計與預測：按配銷通路分類，2021 - 2032 年
- 主要趨勢
- 醫院藥房
- 零售藥房
- 網路藥房
第 9 章：市場估計與預測：按地區，2021 - 2032
- 主要趨勢
- 北美洲
- 美國
- 加拿大
- 歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
- 亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
- 拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
- 中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區
第 10 章：公司簡介
- Accord Healthcare Limited
- Apotex Inc.
- Amneal Pharmaceuticals, Inc.
- Actiza Pharmaceutical Private Limited
- Biocon Limited
- Concept Medical
- Concord Biotech
- Dr. Reddy's Laboratories Ltd.
- Intas Pharmaceuticals Ltd.
- Livzon Pharmaceuticals Group Inc.
- Pfizer Inc.
- Tiefenbacher API + Ingredients GmbH & Co. KG
- Torrent Pharmaceuticals Ltd.
- Zydus Group
Sirolimus Market size is estimated to expand at 3.6% CAGR between 2024 and 2032. The increasing incidence of organ transplantations and the rising use of sirolimus as an immunosuppressant to prevent organ rejection is driving the industry growth. The rising prevalence of various diseases, such as cancer, lymphangioleiomyomatosis (LAM), and coronary artery disease is spurring the demand for sirolimus-based therapies.
According to data from United Network of Organ Sharing, more than 46,000 organ transplants were performed in the U.S. in 2023. The rising cases of organ transplants is increasing the demand for sirolimus. The ongoing clinical trials investigating the efficacy of sirolimus in treating various medical conditions is increasing their market appeal. Significant advancements in drug delivery technologies and the introduction of generic formulations are enhancing accessibility and affordability, further driving the widespread adoption of sirolimus-based medications.
The sirolimus industry is bifurcated into application, route of administration, dosage, distribution channel, and region.
Based on application, the market size from the Lymphangioleiomyomatosis (LAM) segment is estimated to grow at 3.4% CAGR between 2024 and 2032. This is owing to the lack of effective treatment options for LAM, a rare and progressive lung disease primarily affecting women. Sirolimus has demonstrated efficacy in stabilizing lung function and reducing symptoms in LAM patients. The increasing awareness about sirolimus as a therapeutic option for LAM and the ongoing clinical research will further drive the segment growth.
With respect to route of administration, the sirolimus industry from the injection segment will depict 3.8% CAGR through 2032, due to the rising need for targeted and controlled drug delivery, especially in transplant patients requiring immunosuppression. Injectable formulations of sirolimus offer precise dosing and rapid onset of action, making them suitable for post-transplant care. These injections also ensure systemic distribution of the drug, optimizing therapeutic outcomes. Significant advances in injection technologies for improving patient convenience and compliance will add to the segment growth.
Regionally, the Europe sirolimus market is estimated to depict 3.2% gains from 2024 and 2032, driven by the increasing prevalence of chronic diseases requiring immunosuppressive therapy, including organ transplantations and autoimmune disorders. Additionally, the adoption of sirolimus in oncology for the treatment of various cancers across the region is growing. Moreover, favorable government initiatives supporting organ donation and transplantation, coupled with advancements in healthcare infrastructure will further stimulate the demand for sirolimus-based medications in the region.
Table of Contents
Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Rising incidence of organ transplants
- 3.2.1.2 Promising pipeline for different indications
- 3.2.1.3 Advancements in drug delivery systems
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 Adverse effects associated with sirolimus
- 3.2.1 Growth drivers
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Technological landscape
- 3.6 Porter's analysis
- 3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company market share analysis
- 4.3 Competitive positioning matrix
- 4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Organ transplant rejection
- 5.3 Lymphangioleiomyomatosis (LAM)
- 5.4 Sirolimus coated balloons and catheter devices
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Injection
- 6.3 Tablets
Chapter 7 Market Estimates and Forecast, By Dosage, 2021- 2032 ($ Mn)
- 7.1 Key trends
- 7.2 0.5mg
- 7.3 1mg
- 7.4 2mg
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)
- 8.1 key trends
- 8.2 Hospital pharmacy
- 8.3 Retail pharmacy
- 8.4 Online pharmacy
Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
- 9.4 Asia Pacific
- 9.4.1 Japan
- 9.4.2 China
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
- 9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
- 9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
- 10.1 Accord Healthcare Limited
- 10.2 Apotex Inc.
- 10.3 Amneal Pharmaceuticals, Inc.
- 10.4 Actiza Pharmaceutical Private Limited
- 10.5 Biocon Limited
- 10.6 Concept Medical
- 10.7 Concord Biotech
- 10.8 Dr. Reddy's Laboratories Ltd.
- 10.9 Intas Pharmaceuticals Ltd.
- 10.10 Livzon Pharmaceuticals Group Inc.
- 10.11 Pfizer Inc.
- 10.12 Tiefenbacher API + Ingredients GmbH & Co. KG
- 10.13 Torrent Pharmaceuticals Ltd.
- 10.14 Zydus Group
